Connect Biopharma Limited Statistics
Share Statistics
Connect Biopharma Limited has 55.25M shares outstanding. The number of shares has increased by 0.33% in one year.
| Shares Outstanding | 55.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 53.25M |
| Failed to Deliver (FTD) Shares | 229 |
| FTD / Avg. Volume | 0.79% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.09 and the forward PE ratio is -5.2.
| PE Ratio | -1.09 |
| Forward PE | -5.2 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.64 |
| P/FCF Ratio | -1.35 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Connect Biopharma Limited.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.99, with a Debt / Equity ratio of 0.
| Current Ratio | 4.99 |
| Quick Ratio | 4.99 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.46 |
| Cash Flow / Debt | -103.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -61.28%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.47% |
| Return on Capital (ROIC) | -61.28% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -734.60K |
| Employee Count | 81 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 120.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 1.94% in the last 52 weeks. The beta is -0.31, so Connect Biopharma Limited's price volatility has been lower than the market average.
| Beta | -0.31 |
| 52-Week Price Change | 1.94% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | 1.33 |
| Relative Strength Index (RSI) | 46.29 |
| Average Volume (20 Days) | 28.83K |
Income Statement
| Revenue | n/a |
| Gross Profit | -988.00K |
| Operating Income | -62.07M |
| Net Income | -59.50M |
| EBITDA | -58.37M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
The company has 106.01M in cash and 465.00K in debt, giving a net cash position of 105.54M.
| Cash & Cash Equivalents | 106.01M |
| Total Debt | 465.00K |
| Net Cash | 105.54M |
| Retained Earnings | -539.35M |
| Total Assets | 120.57M |
| Working Capital | 106.27M |
Cash Flow
In the last 12 months, operating cash flow was -47.93M and capital expenditures -294.00K, giving a free cash flow of -48.22M.
| Operating Cash Flow | -47.93M |
| Capital Expenditures | -294.00K |
| Free Cash Flow | -48.22M |
| FCF Per Share | -0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -102.86% |
| FCF Yield | -83.11% |
Analyst Forecast
The average price target for CNTB is $8, which is 661.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 661.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -1.7 |
| Piotroski F-Score | 5 |